BioCentury
ARTICLE | Financial News

Amplyx raises $40.5M series B

November 12, 2015 1:29 AM UTC

Amplyx Pharmaceuticals Inc. raised $40.5 million in a series B round led by RiverVest Venture Partners. Other investors included New Enterprise Associates, BioMed Ventures and undisclosed individuals. Next year, the company plans to start Phase I testing of APX001, a broad-spectrum antifungal that Amplyx in-licensed from an undisclosed pharma company earlier this year.

RiverVest's Niall O'Donnell and NEA's Ed Mathers joined Amplyx's board. The biotech also installed a trio of new executives, including President and CEO Mike Grey, COO Ciara Kennedy and Susan Dube, who is VP of business development and administration. All three worked at Lumena Pharmaceuticals Inc., which Shire plc (LSE:SHP; NASDAQ:SHPG) acquired. ...